A Phase 1/2 interventional study of UCMSCs and BMMSCs in Endothelial Dysfunction, Metabolic Syndrome and Chronic Inflammation, sponsored by Joshua M Hare. Terminated at 1 site in United States. Open to participants aged 21 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Joshua M Hare · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.
Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 433rd largest by enrollment of the 490 interventional ones that give a count, is one of 29 that started in 2018, is one of 12 in phase 1/2, and was the 355th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
Northwell Health · Sites in United States
Ages 21–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
University of Virginia · Sites in United States
Ages 6–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 21 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
578 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 68 · Phase 3 20 · Phase 4 44
First in 1982; this study’s year is marked. 29 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 48 across the 490 interventional studies, 141 across the 86 observational. Of the 443 that completed or were terminated, 136 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 578 have an industry lead sponsor. The 10 most frequent:
Joshua M Hare is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Joshua M Hare has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
28 of the studies in Metabolic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT07095426Ball State UniversityImpact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes | 2026-11 |
| NCT04974554Medical University of South CarolinaFIT Families Multicomponent Obesity Intervention for African American Adolescents | 2026-11-30 |
| NCT05943626University of UtahCircadian Intervention to Improve Cardiometabolic Health | 2026-12 |
| NCT05654142University of Illinois at ChicagoThe PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older | 2026-12-31 |
Add all 28 to your calendar (.ics) → With an account.
Among the 578 studies in Metabolic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Endothelial dysfunction Criteria:
Impaired flow-mediated vasodilation (FMD \<7%)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three (3) subjects will be treated with a single administration of 2 x 10\^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Three (3) subjects will be treated with a single IV administration of 2 x 10\^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
Biological: BMMSCs
Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
Biological: BMMSCs
Participants randomized to receive a single administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Participants randomized to receive a single administration of 1 x 10\^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
Biological: BMMSCs
Participants randomized to receive a single administration of placebo via peripheral intravenous infusion.
Other: Placebo
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
a single administration of placebo delivered via peripheral intravenous infusion.
Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.
Time frame: one month post infusion
Cytokine Levels
Cytokine levels including the following panel of inflammatory and angiogenic markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFα), and Vascular Endothelial Growth Factor (VEGF), \& Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples all measured in pg/mL.
Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
hsCRP Levels
values at baseline and follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.
Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Stem Cell Factor (SCF) Levels
SCF levels from serum/plasma samples measured in units of mg/mL
Time frame: at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)
Endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay
Time frame: at Baseline, and at 3 months
Flow Mediated Diameter Percentage (FMD%)
FMD% will be assessed using brachial artery ultrasound
Time frame: at Baseline and at Month 3
No subjects had been randomized to Group A or C at the time of trial termination.
| Milestone | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 0 | 2 | 0 |
| Completed | 3 | 3 | 3 | 3 | 0 | 2 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.
| Events | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Number of Treatment-Emergent Serious Adverse Events (TE-SAEs) | 0 | 0 | 0 | 0 | — | 0 | — |
Cytokine levels including the following panel of inflammatory and angiogenic markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFα), and Vascular Endothelial Growth Factor (VEGF), \& Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples all measured in pg/mL.
| pg/mL | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| IL-6 Baseline | 5.7 ± 4.8 | 2.7 ± 1.8 | 3.2 ± 2.5 | 2.9 ± 1.9 | — | 1.2 ± 0.6 | — |
| IL-6 Week 2 | 5.8 ± 5.2 | 3.4 ± 1.0 | 5.4 ± 6.7 | 3.7 ± 2.3 | — | 1.4 ± 0.4 | — |
| IL-6 Month 1 | 5.4 ± 3.9 | 2.8 ± 1.0 | 2.5 ± 1.0 | 2.1 ± 0.9 | — | 1.3 | — |
| IL-6 Month 3 | 8.4 ± 4.5 | 2.5 ± 1.2 | 1.9 ± 0.6 | 2.3 ± 1.0 | — | — | — |
| IL-6 Month 6 | 2.9 ± 2.2 | 3.2 ± 1.3 | 3.8 ± 3.0 | 2.2 ± 0.4 | — | — | — |
| TNFa Baseline | 1.7 ± 0.4 | 1.6 ± 0.4 | 1.6 ± 0.8 | 2.1 ± 0.5 | — | 1.1 ± 0.2 | — |
| TNFa Week 2 | 1.9 ± 0.8 | 1.5 ± 0.6 | 1.5 ± 0.6 | 2.1 ± 0.7 | — | 0.9 ± 0.3 | — |
| TNFa Month 1 | 1.7 ± 1.1 | 1.5 ± 0.3 | 2.0 ± 0.9 | 2.2 ± 0.8 | — | 0.7 | — |
| TNFa Month 3 | 2.2 ± 1.7 | 1.2 ± 0.5 | 1.8 ± 1.0 | 1.8 ± 0.5 | — | 0.7 | — |
| TNFa Month 6 | 1.5 ± 0.6 | 1.4 ± 0.3 | 1.4 ± 0.3 | 1.0 ± 0.5 | — | 0.5 | — |
| VEGF Baseline | 13.5 ± 4.8 | 19.2 ± 9 | 25.1 ± 14 | 13.5 ± 1.7 | — | — | — |
| VEGF Month 3 | 15.3 ± 3 | 16.5 ± 12.4 | 15.5 ± 6.4 | 9.5 ± 1.8 | — | — | — |
values at baseline and follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.
| mg/L | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Baseline | 2.0 ± 1.6 | 13.0 ± 19.2 | 1.4 ± 0.4 | 3.2 ± 1.9 | — | 0.5 ± 0.3 | — |
| Week 2 | 9.2 ± 14.4 | 5.7 ± 6.0 | 1.7 ± 1.4 | 4.3 ± 3.3 | — | 0.6 ± 0.3 | — |
| Month 1 | 10.7 ± 16.0 | 4.6 ± 4.0 | 2.1 ± 1.4 | 2.9 ± 1.2 | — | 0.6 | — |
| Month 3 | 5.0 ± 3.4 | 4.7 ± 5.1 | 2.7 ± 2.9 | 3.4 ± 1.3 | — | 0.9 | — |
| Month 6 | 1.6 ± 1.1 | 5.4 ± 7.0 | 2.6 ± 1.2 | 2.1 | — | 0.6 | — |
SCF levels from serum/plasma samples measured in units of mg/mL
No measurements were reported for this outcome.
Endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay
| Colony Forming Units per Well | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Baseline | 15.0 ± 14.5 | 0.8 ± 0.9 | 2.3 ± 3.1 | 4.8 ± 6.6 | — | 0.6 ± 0.6 | — |
| Month 3 | 20.4 ± 20.8 | 1.3 ± 1.1 | 13.2 ± 13.6 | 1.9 ± 2.0 | — | — | — |
FMD% will be assessed using brachial artery ultrasound
| percentage of change in brachial artery | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Baseline | 3.6 ± 2.0 | 4.1 ± 1.1 | 3.6 ± 0.8 | 3.1 ± 1.4 | — | 5.0 ± 0.8 | — |
| Month 3 | 3.5 ± 1.9 | 5.4 ± 3.7 | 5.4 ± 0.5 | 4.0 ± 0.8 | — | — | — |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pilot Phase: Group 1 (UCMSCs - 20 Million) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Pilot Phase: Group 2 (BMMSCs - 20 Million) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Pilot Phase: Group 3 (UCMSCs - 100 Million) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Pilot Phase: Group 4 (BMMSCs -100 Million) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Group A (UCMSCs - 100 Million) | — | — | — |
| Group B (BMMSCs - 100 Million) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Group C (Placebo) | — | — | — |
| Event | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Esophageal PerforationGastrointestinal disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| SepsisInfections and infestations | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| Event | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) |
|---|---|---|---|---|---|---|---|
| Upper Respiratory InfectionInfections and infestations | 3/3 | 2/3 | 0/3 | 2/3 | — | 0/2 | — |
| AnemiaBlood and lymphatic system disorders | 2/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| Toe FractureInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/3 | — | 1/2 | — |
| Monoclonal Gammopathy of Uncertain SignificanceBlood and lymphatic system disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 0/3 | — | 0/2 | — |
| Congestive Heart FalureCardiac disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| Atrial FibrillationCardiac disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
| Periorbital HematomaEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | — | 0/2 | — |
Randomized phase of the study was terminated after only 2 participants. No subjects were allocated to Group A or Group C in the randomized phase of the trial.
| Age, Continuous(years) | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 85.67 ± 5.13 | 62.00 ± 8.72 | 61.67 ± 12.9 | 60.67 ± 12.42 | — | 52 ± 12.73 | — | 65.17 ± 13.29 |
| Sex: Female, Male(Participants) | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 3 |
| Male | 2 | 2 | 3 | 2 | 0 | 2 | 0 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 5 |
| Not Hispanic or Latino | 3 | 2 | 2 | 1 | 0 | 1 | 0 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pilot Phase: Group 1 (UCMSCs - 20 Million) | Pilot Phase: Group 2 (BMMSCs - 20 Million) | Pilot Phase: Group 3 (UCMSCs - 100 Million) | Pilot Phase: Group 4 (BMMSCs -100 Million) | Group A (UCMSCs - 100 Million) | Group B (BMMSCs - 100 Million) | Group C (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 2 | 3 | 3 | 2 | 0 | 1 | 0 | 11 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Mar 2020, 23 months.
Results were first posted in Nov 2022, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joshua M Hare